Solid Biosciences: Funding, Investors & Team (Sep 2026)
Solid Biosciences aims to find a cure for Duchenne muscular dystrophy (DMD), a genetic disease that mainly affects boys and typically shows symptoms between the ages of three and five. DMD is a progressive, irreversible, and often fatal condition that affects a small percentage of male births, with approximately 10,000 to 15,000 cases in the US alone. Currently, there is no cure for DMD and very limited treatment options. Their leading product candidate, SGT-001, is a gene transfer therapy designed to restore functional dystrophin protein in patients' muscles. Through their research, they believe that SGT-001 has the potential to slow or stop the progression of DMD. The company has licensed components of SGT-001 from various universities and has received regulatory designations for rare pediatric disease and orphan drug in the US and EU. SGT-001 is currently undergoing evaluation in a Phase I/II clinical trial to determine its safety and efficacy.
Solid Biosciences has raised $440M across 2 funding rounds on record, the most recent an undisclosed round of $240M announced in Mar 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Solid Biosciences Company Profile and Key Stats
Latest funding round on record: Mar 2026.
Solid Biosciences Funding Rounds
Solid Biosciences raised $200M in an undisclosed round announced in Feb 2025.
1.1 years later, an undisclosed round of $240M was announced in Mar 2026.
Solid Biosciences Founders and Leadership Team
Contact details for the Solid Biosciences team: 1 has a LinkedIn profile.
Start 14-day free trial →Solid Biosciences Funding Compared to Other Biotechnology Startups
Solid Biosciences' latest round of $240M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Solid Biosciences in Biotechnology and Marlborough
Companies Similar to Solid Biosciences
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Solid Biosciences Funding FAQs
What does Solid Biosciences do?
Solid Biosciences aims to find a cure for Duchenne muscular dystrophy (DMD), a genetic disease that mainly affects boys and typically shows symptoms between the ages of three and five. DMD is a progressive, irreversible, and often fatal condition that affects a small percentage of male births, with approximately 10,000 to 15,000 cases in the US alone. Currently, there is no cure for DMD and very limited treatment options. Their leading product candidate, SGT-001, is a gene transfer therapy designed to restore functional dystrophin protein in patients' muscles. Through their research, they believe that SGT-001 has the potential to slow or stop the progression of DMD. The company has licensed components of SGT-001 from various universities and has received regulatory designations for rare pediatric disease and orphan drug in the US and EU. SGT-001 is currently undergoing evaluation in a Phase I/II clinical trial to determine its safety and efficacy.
How much funding has Solid Biosciences raised?
Solid Biosciences has raised $440M across 2 rounds on record. The most recent is an undisclosed round of $240M announced in Mar 2026.
When did Solid Biosciences last raise funding?
Solid Biosciences' most recent funding round on record is an undisclosed round of $240M, announced in Mar 2026.
Who founded Solid Biosciences?
FundedIQ lists Bo Cumbo (Founder), Ilan Ganot (Founder) at Solid Biosciences.
Where is Solid Biosciences headquartered?
Solid Biosciences is based in Marlborough, Massachusetts, United States.
How many employees does Solid Biosciences have?
Solid Biosciences is in the 51-100 employee band.
How does Solid Biosciences' funding compare to other Biotechnology startups?
Solid Biosciences' latest round of $240M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Solid Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Solid Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.